Answers are grounded in this paper and cite their sources.
Background Multiple myeloma (MM) is an incurable hematological malignancy characterized by progressive immune dysfunction. While marrow-localized changes are documented, systemic immune dysregulation in newly diagnosed multiple myeloma (NDMM) remains poorly understood. Methods To investigate peripheral immune dysfunction, we analyzed circulating B-cell subsets and antigen-presenting cells (APCs) in NDMM patients and healthy donors using multiparametric flow cytometry to characterize subset distribution and phenotypic alterations. Results NDMM patients exhibited selective expansion of CD19⁺CD27high memory B cells, PD-L1⁺ B cells, and regulatory B cells (Bregs). Conversely, plasmacytoid dendritic cells (pDCs) were significantly reduced. Frequencies of NK cells, conventional DCs, and myeloid-derived suppressor cells (MDSCs) showed no significant differences. Conclusion These findings reveal B-cell-centric immunoregulatory reprogramming in NDMM, characterized by enhanced immune checkpoint activation. The expansion of PD-L1⁺ B cells and the decrease in pDC levels may facilitate early systemic immune escape, offering new insights into MM progression.
No takes yet. Share an insight, caveat, or question.
Vig et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: